随着The Oncology Institute, Inc. (NASDAQ: TOI)高管团队的变动，投资者和利益相关者正密切关注公司的财务状况和市场地位。根据InvestingPro数据，TOI目前的市值为2212万美元。虽然该公司在截至2024年第二季度的过去十二个月内实现了23.31%的可观收入增长，但值得注意的是，TOI在同期并未盈利，营业利润率为-17.62%。

制药公司Mural Oncology plc (NASDAQ: MURA)周一宣布任命Sachiyo Minegishi加入其董事会。 根据Nasdaq规则，Minegishi被认定为独立董事，她还将担任审计委员会主席和提名与公司治理委员会成员。她的任期将于公司2025年年度股东大会结束时届满。

Were you SEEN at Rock Your Style, a fashion show featuring local "movers and shakers" to benefit the New York Oncology ...

Elevation Oncology has won Food and Drug Administration fast-track designation for EO-3021, its lead drug candidate, in certain patients with gastrointestinal cancers.

Cardinal Health on Friday agreed to acquire community cancer center operator Integrated Oncology Network for $1.12 billion in ...

Cardinal Health on Friday agreed to acquire community cancer center operator Integrated Oncology Network for $1.12 billion in cash, marking its expansion into cancer care. The Dublin, Ohio-based ...

2024年9月19日，国际肿瘤学领域权威期刊《JAMA ...

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

This report is a review of recent and emerging trends that promise to make radiation oncology for prostate cancer more ...

Hematology-Oncology Associates of CNY has opened a new 21,000-square-foot Comprehensive Cancer Center in Camillus. Located at ...

Kids facing cancer, along with their parents and medical teams, have a night of fun, music and dancing as the kids perform in ...

Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...